CYP11B1, Polyclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Rabbit IgG

Rabbit

Human.
No cross reactivity with other proteins

Immunogen affinity purified.

Lyophilized

At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time. Avoid repeated freezing and thawing.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of anti-CYP11B1 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

CYP11B1(Cytochrome p450, family 11, subfamily B, polypeptide 1), also called Steroid 11-beta-hydroxylase or P450C11, is a steroid hydroxylase found in the zona fasciculata. The CYP11B1 gene functions primarily in mitochondria in the zona fasciculata of the adrenal cortex to convert 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone. CYP11B1 is a member of the cytochrome P450 superfamily of enzymes. It is mapped on 8q24.3. The CYP11B1 gene contains 9 exons and spans 6.5 kb. Using RT-PCR, Kayes-Wandover and White detected CYP11B1 mRNA in human cardiac tissue samples from left and right atria, aorta, apex, intraventricular septum, and atrioventricular node, as well as whole ***** and fetal heart. Ventricles did not express CYP11B1. In patients with 11-beta-hydroxylase deficiency leading to hypertension and congenital adrenal hyperplasia, Pascoe et al. identified mutations in the CYP11B1 gene.

Western Blot (WB)

Western blot
Concentration: 0.1-0.5 ug/ml
Tested Species: Human

Other applications have not been tested.
Optimal dilutions should be determined by end user.

Anti-CYP11B1 antibody, MBS175139, Western blotting
All lanes: Anti CYP11B1 (MBS175139) at 0.5ug/ml
Lane 1: HELA Whole Cell Lysate at 40ug
Lane 2: U87 Whole Cell Lysate at 40ug
Lane 3: MM231 Whole Cell Lysate at 40ug
Lane 4: PANC Whole Cell Lysate at 40ug
Lane 5: MM453 Whole Cell Lysate at 40ug
Lane 6: HELA Whole Cell Lysate at 40ug
Lane 7: SMMC Whole Cell Lysate at 40ug
Predicted bind size: 58KD
Observed bind size: 58KD

cytochrome P450, family 11, subfamily B, polypeptide 1

cytochrome P450 11B1, mitochondrial; CYPXIB1; cytochrome P450C11; cytochrome P-450c11; cytochrome p450 XIB1; steroid 11-beta-hydroxylase; steroid 11-beta-monooxygenase; cytochrome P450, subfamily XIB (steroid 11-beta-hydroxylase), polypeptide 1

Cytochrome P450 11B1, mitochondrial

S11BH; Cytochrome P450C11  [Similar Products]

C11B1_HUMAN

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the mitochondrial inner membrane and is involved in the conversion of progesterone to cortisol in the adrenal cortex. Mutations in this gene cause congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency. Transcript variants encoding different isoforms have been noted for this gene. [provided by RefSeq, Jul 2008]

CYP11B1: Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB. Defects in CYP11B1 are the cause of adrenal hyperplasia type 4 (AH4). AH4 is a form of congenital adrenal hyperplasia, a common recessive disease due to defective synthesis of cortisol. Congenital adrenal hyperplasia is characterized by androgen excess leading to ambiguous genitalia in affected females, rapid somatic growth during childhood in both sexes with premature closure of the epiphyses and short ***** stature. Four clinical types: salt wasting (SW, the most severe type), simple virilizing (SV, less severely affected patients), with normal aldosterone biosynthesis, non-classic form or late onset (NC or LOAH), and cryptic (asymptomatic). AH4 patients usually have hypertension. Defects in CYP11B1 are a cause of familial hyperaldosteronism type 1 (FH1). It is a disorder characterized by hypertension, variable hyperaldosteronism, and abnormal adrenal steroid production, including 18-oxocortisol and 18-hydroxycortisol. There is significant phenotypic heterogeneity, and some individuals never develop hypertension. The molecular defect causing hyperaldosteronism familial type 1 is an anti-Lepore-type fusion of the CYP11B1 and CYP11B2 genes. The hybrid gene has the promoting part of CYP11B1, ACTH-sensitive, and the coding part of CYP11B2. Belongs to the cytochrome P450 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Oxidoreductase; EC 1.14.15.4; Lipid Metabolism - C21-steroid hormone; Mitochondrial; Lipid Metabolism - androgen and estrogen

Chromosomal Location of Human Ortholog: 8q21

Cellular Component: mitochondrion; mitochondrial inner membrane

Molecular Function: steroid 11-beta-monooxygenase activity; iron ion binding; heme binding

Biological Process: steroid metabolic process; regulation of blood pressure; xenobiotic metabolic process; C21-steroid hormone biosynthetic process; immune response; glucocorticoid biosynthetic process; glucose homeostasis; sterol metabolic process; aldosterone biosynthetic process; cellular response to hormone stimulus

Disease: Glucocorticoid-remediable Aldosteronism; Adrenal Hyperplasia, Congenital, Due To Steroid 11-beta-hydroxylase Deficiency

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.